What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

BioCryst Pharmaceuticals BCRX Return on equity

Discontinued — last reported Q1 '20

Return on equity at other companies

Ionis PharmaceuticalsIONS

-67.6%-20.3pp

Ultragenyx PharmaceuticalRARE

-325.6%+36.9pp

Arrowhead ResearchARWR

-46.4%+341pp

Agios PharmaceuticalsAGIO

-32.8%—

ALN

Alnylam PharmaceuticalsALNY

66.9%—

PrecigenPGEN

-843.6%-1,103pp

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

net income/total stockholders equity=-882.8%

Based on trailing twelve months.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 11, 2020, on SEC EDGAR. View the filing →

Questions, answered.

What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.